ORAMED PHARMACEUTICALS INC. (ORMP) Return on equity 2016–2025
ORAMED PHARMACEUTICALS INC. (ORMP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
32.1%FY2025 · since FY2016: -41.9% → 32.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 32.1% | — |
| FY2023 | 3.1% | +27.2 pp |
| FY2022 | -24.1% | -4.2 pp |
| FY2021 | -19.9% | +15.2 pp |
| FY2020 | -35.0% | +39.0 pp |
| FY2019 | -74.0% | -33.1 pp |
| FY2018 | -40.9% | +13.6 pp |
| FY2017 | -54.5% | -12.6 pp |
| FY2016 | -41.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ORMP financial trends
ORMP RevenueORMP Net incomeORMP Net marginORMP Gross profitORMP Gross marginORMP Operating incomeORMP Operating marginORMP Operating cash flowORMP Free cash flowORMP Capital expendituresORMP Stock buybacksORMP Dividends paidORMP Total assetsORMP Total liabilitiesORMP Shareholders’ equityORMP overview →